The importance of p53 pathway genetics in inherited and somatic cancer genomes

Nature Reviews Cancer

Volumn 16, Issue 4, 2016, Pages 251-265

  Stracquadanio, Giovanni ^a   Wang, Xuting ^b   Wallace, Marsha D ^a   Grawenda, Anna M ^a   Zhang, Ping ^a   Hewitt, Juliet ^a   Zeron Medina, Jorge ^c   Castro Giner, Francesc ^d   Tomlinson, Ian P ^d   Goding, Colin R ^a   Cygan, Kamil J ^e,f   Fairbrother, William G ^e,f   F Thomas, Laurent ^g   Sætrom, Pal ^g   Gemignani, Federica ^h   Landi, Stefano ^h   Schuster Böckler, Benjamin ^a   Bell, Douglas A ^b   Bond, Gareth L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BROWN UNIVERSITY   (United States)

^f BROWN UNIVERSITY   (United States)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; GENETIC PREDISPOSITION; GENETICS; HUMAN GENOME; MUTATION; NEOPLASM;

GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84962311192     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.15     Document Type: Article

References (119)

1. Vogelstein B, et al. Cancer genome landscapes. Science. 339, 1546-1558 (2013).
2. Edwards S. L, Beesley J, French J. D, & Dunning A. M. Beyond GWASs: illuminating the dark road from association to function. Am. J. Hum. Genet. 93, 779-797 (2013).
3. Manolio T. A. Bringing genome-wide association findings into clinical use. Nat. Rev. Genet. 14, 549-558 (2013).
4. The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 526, 68-74 (2015).
5. Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 489, 57-74 (2012).
6. Schodel J, et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, 420-425 (2012).
7. Sur I. K, et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science. 338, 1360-1363 (2012).
8. Zeron-Medina J, et al. A polymorphic p53 response element in KIT ligand influences cancer risk, and has undergone natural selection. Cell. 155, 410-422 (2013).
9. Cookson W, Liang L, Abecasis G, Moffatt M, & Lathrop M. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 10, 184-194 (2009).
10. Stranger B. E, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 8, e1002639 (2012).
11. Veyrieras J. B, et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet. 4, e1000214 (2008).
12. Nica A. C, et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 6, e1000895 (2010).
13. Nicolae D. L, et al. Trait-Associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 6, e1000888 (2010).
14. McBride K. A, et al. Li Fraumeni syndrome: cancer risk assessment, and clinical management. Nat. Rev. Clin. Oncol. 11, 260-271 (2014).
15. Merino D, & Malkin D. p53, and hereditary cancer. Subcell. Biochem. 85, 1-16 (2014).
16. Vazquez A, Bond E. E, Levine A. J, & Bond G. L. The genetics of the p53 pathway, apoptosis, and cancer therapy. Nat. Rev. Drug Discov. 7, 979-987 (2008).
17. Grochola L. F, Zeron-Medina J, Meriaux S, & Bond G. L. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb. Perspect. Biol. 2, a001032 (2010).
18. Whibley C, & Pharoah P. D, & Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer. 9, 95-107 (2009).
19. Kandoth C, et al. Mutational landscape, and significance across 12 major cancer types. Nature. 502, 333-339 (2013).
20. Soussi T, Ishioka C, Claustres M, & Beroud C. Locus-specific mutation databases: pitfalls, and good practice based on the p53 experience. Nat. Rev. Cancer. 6, 83-90 (2006).
21. Leroy B, et al. The TP53 website: an integrative resource centre for the TP53 mutation database, and TP53 mutant analysis. Nucleic Acids Res. 41, D962-D969 (2013).
22. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes, and core pathways. Nature. 455, 1061-1068 (2008).
23. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490, 61-70 (2012).
24. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499, 43-49 (2013).
25. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489, 519-525 (2012).
26. Kandoth C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 497, 67-73 (2013).
27. Leiserson M. D, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways, and protein complexes. Nat. Genet. 47, 106-114 (2015).
28. Khoo K. H, Verma C. S, & Lane D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236 (2014).
29. Muller P. A, & Vousden K. H. Mutant p53 in cancer: new functions, and therapeutic opportunities. Cancer Cell. 25, 304-317 (2014).
30. Wade M, Li Y. C, & Wahl G. M. MDM2, MDMX, and p53 in oncogenesis, and cancer therapy. Nat. Rev. Cancer. 13, 83-96 (2013).
31. Ventura A, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 445, 661-665 (2007).
32. Xue W, et al. Senescence, and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 445, 656-660 (2007).
33. Riley T, Sontag E, Chen P, & Levine A. Transcriptional control of human p53 regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412 (2008).
34. Muller P. A, Vousden K. H, & Norman J. C. p53, and its mutants in tumor cell migration, and invasion. J. Cell Biol. 192, 209-218 (2011).
35. Muller P. A, & Vousden K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2-8 (2013).
36. Futreal P. A, et al. A census of human cancer genes. Nat. Rev. Cancer. 4, 177-183 (2004).
37. Brown C. D, Mangravite L. M, & Engelhardt B. E. Integrative modeling of eQTLs, and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet. 9, e1003649 (2013).
38. Fairfax B. P, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators, and roles of HLA alleles. Nat. Genet. 44, 502-510 (2012).
39. Fehrmann R. S, et al. Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet. 7, e1002197 (2011).
40. Gaffney D. J, et al. Dissecting the regulatory architecture of gene expression QTLs. Genome Biol. 13, R7 (2012).
41. Grundberg E, et al. Mapping cis-, and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-1089 (2012).
42. Hao K, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet. 8, e1003029 (2012).
43. Innocenti F, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7, e1002078 (2011).
44. Liang L, et al. A cross-platform analysis of 14,177 expression quantitative trait loci derived from lymphoblastoid cell lines. Genome Res. 23, 716-726 (2013).
45. Schadt E. E, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107 (2008).
46. Zeller T, et al. Genetics, and beyond-The transcriptome of human monocytes, and disease susceptibility. PLoS ONE 5, e10693 (2010).
47. Bryois J, et al. Cis, and trans effects of human genomic variants on gene expression. PLoS Genet. 10, e1004461 (2014).
48. Fairfax B. P, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 343, 1246949 (2014).
49. Kabakchiev B, & Silverberg M. S. Expression quantitative trait loci analysis identifies associations between genotype, and gene expression in human intestine. Gastroenterology. 144, 1488-1496 (2013).
50. Koopmann T. T, et al. Genome-wide identification of expression quantitative trait loci (eQTLs) in human heart. PLoS ONE 9, e97380 (2014).
51. Raj T, et al. Polarization of the effects of autoimmune, and neurodegenerative risk alleles in leukocytes. Science. 344, 519-523 (2014).
52. Alves da Costa C, et al. Presenilin-dependent ã-secretase-mediated control of p53 associated cell death in Alzheimer's disease. J. Neurosci. 26, 6377-6385 (2006).
53. Fogarty M. P, et al. A role for p53 in the β-Amyloid-mediated regulation of the lysosomal system. Neurobiol. Aging. 31, 1774-1786 (2010).
54. Perier C, et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc. Natl Acad. Sci. USA. 104, 8161-8166 (2007).
55. Alves da Costa C, et al. Transcriptional repression of p53 by parkin, and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat. Cell Biol. 11, 1370-1375 (2009).
56. Feng Z, et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene. 25, 1-7 (2006).
57. Matsumoto S, et al. Circulating p53 responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ. Res. 113, 322-326 (2013).
58. Sano M, et al. p53 induced inhibition of Hif 1 causes cardiac dysfunction during pressure overload. Nature. 446, 444-448 (2007).
59. Munoz-Fontela C, et al. p53 serves as a host antiviral factor that enhances innate, and adaptive immune responses to influenza A virus. J. Immunol. 187, 6428-6436 (2011).
60. Takaoka A, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression, and antiviral defence. Nature. 424, 516-523 (2003).
61. Garcia P. B, & Attardi L. D. Illuminating p53 function in cancer with genetically engineered mouse models. Semin. Cell Dev. Biol. 27, 74-85 (2014).
62. Guarini A, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile, and predict disease progression. Haematologica. 97, 47-55 (2012).
63. Renwick A, et al. ATM mutations that cause ataxia-Telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873-875 (2006).
64. Kim H. S, et al. Inactivating mutations of caspase 8 gene in colorectal carcinomas. Gastroenterology. 125, 708-715 (2003).
65. Soung Y. H, et al. Caspase 8 gene is frequently inactivated by the frameshift somatic mutation 1225 1226delTG in hepatocellular carcinomas. Oncogene. 24, 141-147 (2005).
66. Wiestner A, et al. Point mutations, and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate, and shorter survival. Blood. 109, 4599-4606 (2007).
67. Gao Y. B, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102 (2014).
68. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes, and core pathways. Nature. 455, 1061-1068 (2008).
69. Sieuwerts A. M, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin. Cancer Res. 12, 3319-3328 (2006).
70. Nakayama N, et al. Gene amplification CCNE1 is related to poor survival, and potential therapeutic target in ovarian cancer. Cancer. 116, 2621-2634 (2010).
71. Gronbaek K, et al. Concurrent disruption of p16INK4a, and the ARF p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia. 14, 1727-1735 (2000).
72. Holzelova E, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N. Engl. J. Med. 351, 1409-1418 (2004).
73. Dowdell K. C, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 115, 5164-5169 (2010).
74. Park W. S, et al. Somatic mutations in the death domain of the Fas (Apo 1/CD95) gene in gastric cancer. J. Pathol. 193, 162-168 (2001).
75. Gembarska A, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 18, 1239-1247 (2012).
76. Forbes S. A, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
77. Stacey S. N, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43, 1098-1103 (2011).
78. Wang Z, et al. Further confirmation of germline glioma risk variant rs78378222 in TP53, and its implication in tumor tissues via integrative analysis of TCGA data. Hum. Mutat. 36, 684-688 (2015).
79. Weinhold N, et al. The CCND1 c.870GA polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522-525 (2013).
80. Betticher D. C, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 11, 1005-1011 (1995).
81. Comstock C. E, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 15, 5338-5349 (2009).
82. Olshavsky N. A, et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res. 70, 3975-3984 (2010).
83. Knudsen K. E, Diehl J. A, Haiman C. A, & Knudsen E. S. Cyclin D1: polymorphism, aberrant splicing, and cancer risk. Oncogene. 25, 1620-1628 (2006).
84. Kruse J. P, & Gu W. Modes of p53 regulation. Cell. 137, 609-622 (2009).
85. Bieging K. T, & Attardi L. D. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol. 22, 97-106 (2012).
86. Fumagalli S, & Thomas G. The role of p53 in ribosomopathies. Semin. Hematol. 48, 97-105 (2011).
87. McGowan K. A, & Mason P. J. Animal models of Diamond Blackfan anemia. Semin. Hematol. 48, 106-116 (2011).
88. Van Nostrand J. L, & Attardi L. D. Guilty as CHARGED: 53's expanding role in disease. Cell Cycle. 13, 3798-3807 (2014).
89. Van Nostrand J. L, et al. Inappropriate p53 activation during development induces features of CHARGE syndrome. Nature. 514, 228-232 (2014).
90. Adachi M, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs, and liver. Nat. Genet. 11, 294-300 (1995).
91. Adachi M, et al. Enhanced, and accelerated lymphoproliferation in Fas-null mice. Proc. Natl Acad. Sci. USA. 93, 2131-2136 (1996).
92. Barlow C, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 86, 159-171 (1996).
93. Bieging K. T, Mello S. S, & Attardi L. D. Unravelling mechanisms of p53 mediated tumour suppression. Nat. Rev. Cancer. 14, 359-370 (2014).
94. Chen L, et al. CD95 promotes tumour growth. Nature. 465, 492-496 (2010).
95. Deane N. G, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 61, 5389-5395 (2001).
96. Geng Y, et al. Kinase-independent function of cyclin E. Mol. Cell. 25, 127-139 (2007).
97. Geng Y, et al. Cyclin E ablation in the mouse. Cell. 114, 431-443 (2003).
98. Hakem A, et al. Caspase 8 is essential for maintaining chromosomal stability, and suppressing B cell lymphomagenesis. Blood. 119, 3495-3502 (2012).
99. Jiang H, et al. The combined status of ATM, and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
100. Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91, 649-659 (1997).
101. Kwong L. N, Weiss K. R, Haigis K. M, & Dove W. F. Atm is a negative regulator of intestinal neoplasia. Oncogene. 27, 1013-1018 (2008).
102. Liu S. C, et al. Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells. Mol. Carcinogen. 34, 131-139 (2002).
103. Salmena L, et al. Essential role for caspase 8 in T cell homeostasis, and T cell-mediated immunity. Genes Dev. 17, 883-895 (2003).
104. Varfolomeev E. E, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3, and is lethal prenatally. Immunity. 9, 267-276 (1998).
105. Xiong S, et al. Spontaneous Tumorigenesis in Mice Overexpressing the p53 Negative Regulator Mdm4. Cancer Res. 70, 7148-7154 (2010).
106. Post S. M, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 18, 220-230 (2010).
107. Balint E. E, & Vousden K. H. Activation, and activities of the p53 tumour suppressor protein. Br. J. Cancer. 85, 1813-1823 (2001).
108. Feng Z, et al. The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell, and tissue specificity, and the role of these gene products in modulating the IGF 1-AKT-mTOR pathways. Cancer Res. 67, 3043-3053 (2007).
109. Harris S. L, & Levine A. J. The p53 pathway: positive, and negative feedback loops. Oncogene. 24, 2899-2908 (2005).
110. Hofseth L. J, Hussain S. P, & Harris C. C. p53: 25 years after its discovery. Trends Pharmacol. Sci. 25, 177-181 (2004).
111. Levine A. J, Hu W, & Feng Z. the p53 Pathway: What Questions Remain to Be Explored? Cell Death Differ. 13, 1027-1036 (2006).
112. Sherr C. J. Divorcing ARF, and p53: an unsettled case. Nat. Reviews Cancer. 6, 663-673 (2006).
113. Tokino T, & Nakamura Y. The role of p53 target genes in human cancer. Crit. Rev. Oncol. Hematol. 33, 1-6 (2000).
114. Donehower L. A, & Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat. Rev. Cancer. 9, 831-841 (2009).
115. Kamijo T, Bodner S, van de Kamp E, Randle D. H, & Sherr C. J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217-2222 (1999).
116. Spring K, et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-Telangiectasia, have heightened susceptibility to cancer. Nat. Genet. 32, 185-190 (2002).
117. Spring K, et al. Atm knock in mice harboring an in frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype. Cancer Res. 61, 4561-4568 (2001).
118. Wang Y. V, Leblanc M, Wade M, Jochemsen A. G, & Wahl G. M. Increased radioresistance, and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-Activated kinases. Cancer Cell. 16, 33-43 (2009).
119. Yamamoto K, et al. Kinase-dead ATM protein causes genomic instability, and early embryonic lethality in mice. J. Cell Biol. 198, 305-313 (2012).